Formyl-Met-Leu-Phe (fMLP) is a potent chemoattractant molecule released from both bacteria and damaged mitochondria that activates fMLP receptors (FPR) leading to neutrophil chemotaxis, degranulation and superoxide production. A common missense single nucleotide polymorphism in the human FPR1 gene at nucleotide c.32C4T results in the amino-acid substitution, p.I11T, in the FPR1 extracellular amino-terminus. The minor (c.32T) allele frequencies were 0.25, 0.27, 0.25, 0.15 and 0.14 in healthy Caucasian, African, East Indian, Chinese and Native Canadian individuals, respectively. In subjects homozygous for the p.T11 allele, we find elevated serum concentrations of C-reactive protein, increased absolute counts of blood leukocytes and neutrophils, and erythrocyte sedimentation rates. When expressed in HEK 293 and RBL-2H3 cells a substantial proportion of FPR1 p.I11T variant is retained intracellularly and agonist-independent internalization of the FPR1 p.I11T variant, but not the wild-type FPR1, is constitutively associated with b-arrestin2-GFP in vesicles. Moreover, basal N-acetyl-Dglucosaminidase release is increased in primary neutrophils isolated from subjects either heterozygous or homozygous for the FPR1 p.T11 allele. Taken together, the data suggest an increased receptor activity and phenotypic expression of increased inflammatory indices in subjects with the p.T11 allele.
Introduction
Neutrophils play a pivotal role in the inflammatory response and form an important component of the host defense against bacterial infections.
1 In response to inflammatory stimuli, neutrophils are sequestered in the microvasculature, traverse vascular barriers and converge on inflammatory loci. The neutrophil cytoplasm contains an ensemble of granules that contain numerous proteolytic and bactericidal proteins and also serve as reservoirs of membrane proteins that are exocytosed to the plasma membrane when the neutrophils degranulate. These granules are capable of inflicting significant damage upon foreign organisms, as well as host tissues.
The formylated tripeptide formyl-Met-Leu-Phe (fMLP) is one of the most powerful chemoattractants that activates neutrophils. 2 fMLP is released from mitochondria in response to tissue damage and is also derived from bacterial protein degradation. 3 fMLP induces numerous functional responses that contribute to defense mechanisms including chemotaxis, degranulation, release of superoxide and phagocytosis. 4 fMLP mediates these effects by binding a cell surface seven transmembrane, G protein-coupled formyl peptide receptor (FPR1). 5 This receptor couples to pertussis toxin (PTX)-sensitive G-proteins, and mediates activation of phospholipase C via released G protein bg-subunits, resulting in intracellular calcium mobilization and formation of inositol-1,4,5-triphosphate. [5] [6] [7] Disruption of the FPR1 gene in mice increases susceptibility to bacterial infection suggesting a role for FPR1 in antibacterial host defense. 8 Three members of the FPR1 family have been identified, the FPR1 and two FPR1-like proteins, FPRL1 and FPRL2. Whereas the FPR1 binds fMLP with high affinity and is activated by nanomolar concentrations of fMLP, fPRL1 has low affinity for fMLP and responds only to high fMLP concentrations in the micromolar range. 5, 9 FPRL2 is an orphan receptor and does not bind fMLP. 10 The FPR1 and FPRL1 are expressed abundantly on monocytes and granulocytes.
Several single nucleotide polymorphisms (SNPs) in the FPR1 coding region have been reported previously and two have been associated with the disease juvenile periodontitis and reduced chemotactic responses of neutrophils. [11] [12] [13] In this study, we have investigated the significance of an SNP in the human FPR1 gene at nucleotide 32 of the coding region, resulting in the amino-acid substitution, p.I11T, located in the extracellular amino-terminus of the receptor that results in the intracellular accumulation of FPR1 in intracellular vesicles. We find that this polymorphism is not only common in several human populations but that in Canadians of Northern European descent subjects homozygous for the allele exhibit increased blood leukocyte and neutrophil counts as well as increased serum concentration of C-reactive protein (CRP). We find that the FPR1 p.I11T variant is associated with increased basal neutrophil degranulation and agonist-independent recruitment of b-arrestin.
Results
Identification, localization and activity of FPR1 wild-type and p.I11T variants In the process of cloning the FPR1 from a Marathon-Ready human fetal brain cDNA library (Clontech, Cambridge, UK) for a previous study, 13 we identified two common FPR1 variants. One FPR1 variant encodes a threonine residue in the coding region corresponding to codon 11 of the FPR1 amino-terminus. This FPR1 variant, referred to here as the wild-type FPR1 variant, when expressed as green fluorescent protein (GFP) fusions and heterologously expressed in human embryonic kidney (HEK) 293 cells that are commonly used to study FPR1 signaling 9, 13, 14 was predominantly localized to the cell surface (Figure 1a) . When the p.I11T FPR1 variant was expressed as a GFP fusion it was observed to be expressed at the plasma membrane but was also observed to be accumulated intracellularly (Figure 1b) . To test whether the intracellular localization of the p.I11T FPR1-GFP variant was cell type-specific, we examined the subcellular localization of the wild-type and p.I11T FPR1 constructs in rat basophilic leukemia cell line (RBL 2H3). We found that similar to what was observed with HEK 293 cells, both variants could be found at the cell surface and the p.I11T FPR1 was localized to intracellular vesicles in RBL-2H3 cells (Figure 1c and d) . However, in the RBL 2H3 cells, the subcellular localization of the variant was more punctuate than that observed in HEK 293 cells and some intracellular wild-type receptor was also observed (Figure 1c and d). One possibility for the enhanced intracellular localization of the p.I11T FPR1 variant was an increased rate of agonist-independent internalization. When tested, we found that cell surface wild-type and p.I11T FPR1 rapidly internalized in the absence of agonist similar to what has been reported for several other GPCRs [15] [16] [17] [18] [19] [20] [21] (Figure 1e ). However, the rate and extent of agonist-independent endocytosis for the two receptor variants was not significantly different. Rather the intracellular distribution of p.I11T FPR1, at least in HEK 293 cells, was similar to that observed for a GFP-KDEL marker of the ER compartment of the cell (data not shown).
Activation of FPR1 stimulates actin cytoskeletal remodeling necessary for processes such as granule release and cell motility of neutrophils. 7 Previous studies have demonstrated that RBL-2H3 cells transfected with GFP-tagged FPR1 exhibit extensive membrane ruffling in response to fMLP, an indicator of cytoskeletal rearrangement a process that appears to be b-arrestin-dependent.
12,22 fMLP activation of both wild-type and p.I11T FPR1-GFP variants results in RBL-2H3 cell membrane ruffling. Both the wild-type and p.I11T FPR1 variants stimulate RBL-2H3 cell ruffling responses and both receptors internalized following 5 and 15 stimulation with 100 nM fMLP (Figure 2a and b) . The half maximal effective concentration for fMLP-stimulated increases in intracellular Ca 2 þ concentration was increased for the p.I11T FPR1 vs the wild-type FPR1, 84 vs 8 nM, suggesting that the p.I11T FPR1 variant is somewhat G protein-uncoupled. The agonist binding affinity for the wild-type and p.I11T variant FPR1s were roughly equivalent, K D ¼ 371 and 6.273 nM, respectively. Nevertheless, the p.I11T FPR1 variant retains some capacity to signal via both G protein-and b-arrestin-dependent mechanisms in response to agonist stimulation despite being predominantly localized to intracellular vesicles.
Population genetics of FPR1 c.32C4T SNP As outlined above, we found that an SNP in the human FPR1 gene at nucleotide c.32C4T of the coding region corresponding to codon 11, resulted in the amino-acid substitution, p.I11T, located in the extracellular amino terminal domain of the receptor that lead to the intracellular localization of the p.I11T FPR1 variant. Therefore, we examined the prevalence of this variant in different populations of healthy Canadians. Results of genotype and allele frequencies in normal populations are shown in Table 1 . In the first and second samples of Caucasians, the frequency of the 32T allele was, respectively 0.24 and 0.25. In samples of healthy control African, East Indian, Chinese and Native Canadians, the minor allele (T) frequencies were 0.27, 0.25, 0.15 and 0.16, respectively, with no deviation in any sample of the observed genotype frequencies from Hardy-Weinberg expectations. Since the time that we first discovered this SNP through genomic DNA sequence analysis in 2001, the SNP has independently been annotated and its population genetics studied. For instance, it has been given identification number rs5030878 within the dbSNP database (http://www.ncbi.nlm.nih.gov). Population-specific allele frequencies of the T allele in that database include 0.318, 0.229 and 0.083 in samples of African, European and Asian descent, respectively, which are consistent with frequencies that we observed in these ethnic groups.
Genetic association analyses
Because we observed alterations in the subcellular localization, ligand binding and EC 50 for fMLP-stimulated Ca 2 þ release between the wild-type and p.I11T FPR1 variants, we tested association of this polymorphism with indices of leukocyte function and inflammation measured from blood in two independent clinical samples ( Table 2) . Results were the same when quantitative traits were either transformed or untransformed, so untransformed means are shown in Table 2 . The only significant findings for both study samples best fit a recessive model of inheritance (i.e. genotypes C/C or C/T ¼ 0 and T/T ¼ 1), although other models were also tested. Because the only significant results were found using a recessive model, these are the only results that are reported here. It is notable that the recessive model fit best for the significantly associated inflammationrelated traits in both study samples. Under a recessive model, analysis of the first sample showed a significant difference in the leukocyte count in T/T homozygotes compared with others (7.973.9 (mean7standard deviation (s.d.)) vs 6.773.6 Â 10 9 cells per liter, P ¼ 0.015). Also, there was a significant difference in neutrophil count in T/T homozygotes compared with others (5.571.0 vs 4.271.1 Â 10 9 cells per liter, P ¼ 0.005), with no significant differences in other values. Under a recessive model, analysis of the second sample showed a significant difference in the serum concentration of CRP for T/T homozygotes compared with others (8.671.8 vs 4.171.2 g/l, P ¼ 0.0002). Also, under a recessive model, analysis of the second sample showed a significant difference in the mean7s.d. serum concentration of erythrocyte sedimentation rate (ESR) for T/T homozygotes compared with others (17.977.1 vs 12.872.9 mm/h, P ¼ 0.01).
Differences in FPR1 variant degranulation in primary human neutrophils
The association of the p.I11T FPR1 variant with parameters suggesting increased inflammation prompted us to examine whether the variant may be associated with altered granule release from primary human neutrophils. We tested the release of N-acetyl-b-glucosaminidase from primary human Table 2 Clinical and biochemical attributes of study samples according to genotype neutrophils in three subject groups: homozygotes for wildtype FPR1 sequence (C/C), heterozygotes (C/T) or homozygotes for the p.I11T variant sequence (T/T). In the absence of fMLP stimulation, we observed basal release of N-acetyl-bglucosaminidase from isolated neutrophils in each of the subject groups (Figure 3a) . However, basal release was significantly greater for both C/T and T/T individuals compared to C/C individuals (Figure 3a) . For primary neutrophils isolated from C/C individuals, treatment for 10 min with 100 nM results in the release of 2873% of the total cellular complement N-acetyl-D-glucosaminidase (Figure 3a) . In contrast, fMLP treatment results in the release of 4476 and 4273% of the total cellular complement Nacetyl-D-glucosaminidase from neutrophils isolated from C/T and C/C individuals, respectively (Figure 3b ). To control for nonspecific alterations in granule release, we tested the effect of phorbol myristate acetate (PMA) treatment on the release of granule release from primary neutrophils isolated from each of the three subject groups. PMA treatment activates protein kinase C and directly stimulates granule release. 23 However, we find no differences in PMA-stimulated granule release between the three subject groups (Figure 3b ). Taken together, these observations suggest that the p.I11T variant encodes a constitutively active FPR1.
Constitutive p.I11T FPR1 b-arrestin recruitment A substantial proportion of p.I11T FPR1 was localized intracellularly in both HEK 293 cells and RBL-2H3 cells (Figure 1d) , and the p.I11T variant encodes an FPR1 that exhibits constitutive activity in neutrophils isolated from subjects either heterozygous for the p.I11T variant. Therefore, we examined whether cell surface wild-type and p.I11T FPR1 was constitutively internalized in a b-arrestin-dependent manner. HEK 293 cells transiently transfected to express b-arrestin2-GFP along with either wild type or p.I11T HA-FPR1 were cell surface labeled on ice with Alexa Fluor 555 labeled anti-HA antibody diluted 1:500 in Hank's balanced salt solution (HBSS) and then transferred to 371C and imaged every 15 s using a Zeiss LSM 510 META confocal microscope (Yenna, Germany). In the absence of agonist stimulation, wild-type HA-FPR1 was localized to the cell surface and could be found in intracellular vesicles ( Figure  4a , HA-FPR1-WT), whereas b-arrestin2-GFP fluorescence was uniformly distributed throughout the cytosol of the cell and was not colocalized with the internalized receptor ( Figure  4a ). In contrast, fluorescently labeled p.I11T HA-FPR1 was observed both at the cell surface and colocalized with b-arrestin2-GFP in internalized vesicles suggesting that the receptor spontaneously isomerizes to an active conformation that can recruit b-arrestin2 (Figure 4b ). Agonist stimulation of the same cells with 100 nM fMLP results in a dramatic increase in internalized p.I11T HA-FPR1/b-arrestin complexes (Figure 4c ). The confocal data taken together with the quantitative data provided in Figure 1e , indicated that both receptors are constitutively internalized, but that only the p.I11T HA-FPR1 mutant was internalized as a complex with b-arrestin2.
Discussion
In the present study, we have identified a function for a novel SNP in the human FPR1 gene resulting in the aminoacid substitution, p.I11T, which is located in the extracellular amino-terminal domain of the receptor. The frequency of this variant allele was similar in samples of healthy African, Caucasian, East Indian, Chinese and Native Canadian individuals, suggesting that it is common in many human populations. We found that several indices of inflammation, including counts of blood leukocytes and neutrophils, CRP and ESR are elevated in homozygotes for the p.I11T allele compared with others suggesting that carriers of the p.I11T allele might be at risk of increased inflammatory responsiveness. Our data also indicate that the p.I11T FPR1 variant represents a gain of function mutant that leads to increased basal/constitutive granule release in subjects who carry the p.I11T allele. Overall, the data are consistent with an increased inflammatory responsiveness and thus potential increased susceptibility to inflammatory conditions among subjects with the p.I11T allele.
Chemoattractant receptors such as the FPR1 regulate neutrophil degranulation. Granule mobilization and release are important components of neutrophil function in inflammation and to mount the innate immune response against pathological organisms or for fMLP released from damaged cells. 3 Recently, Zhang et al. 24 identified a series of FPR1 SNPs that were associated with aggressive periodontitis in African-American patients. These SNPs are localized to the third transmembrane, second intracellular loop and third extracellular loop domains of the FPR1. This study suggested that the SNPs localized to the third transmembrane domain and third extracellular loop do not appear to play an etiological role in aggressive periodontitis, but the SNPs localized to the second intracellular loop might be etiologically important resulting in loss of FPR1 function. 24 The second intracellular loop domain of G protein-coupled receptors plays an important role in regulating receptor/G protein-coupling 25 and thus mutations in this receptor domain may explain reduced chemotactic responses of neutrophils. 11, 12 In contrast, we have identified a SNP in the extracellular amino-terminal domain of the FPR1 that is associated with a dominant-positive gain of function with respect to the basal release of N-acetyl-b-glucosaminidase from primary human neutrophils. In addition, a substantial proportion of the p.I11T FPR1 variant is localized intracellularly in both HEK 293 and RBL-2H3 cells. However, both receptor variants are constitutively internalized at virtually identical rates suggesting that the increased levels of intracellularly occluded protein observed in HEK 293 cells may be associated with impaired ER/Golgi processing of the p.I11T FPR1 variant. However, of particular interest, the constitutive internalization of the p.I11T FPR1 variant is associated with the redistribution of b-arrestin2-GFP to intracellular vesicular structures, whereas the constitutive internalization of the wild-type receptor is not associated with changes in the distribution of b-arrestin2-GFP. bArrestin-dependent and -independent constitutive internalization have been reported for a growing number of receptors including: Group I metabotropic glutamate receptors, the mu-opioid receptor 1D, galanin R1 and R2 receptors, angiotensin II type 1A receptors, protease-activated receptor 1 and cholecystokinin receptor type A. [15] [16] [17] [18] [19] [20] [21] The fact that the p.I11T FPR1 variant may internalize in a b-arrestin-dependent manner may increase the relative level of receptor protein localized within the endosomal compartment as the potential stable association with b-arrestin may impair the recycling of the receptor back to the cell surface. 26 The expression of the p.I11T FPR1 variant in heterologous cell cultures reveals that the p.I11T variant is associated with reduced coupling to the release of intracellular Ca 2 þ stores and constitutive b-arrestin recruitment, but no apparent change in agonist affinity. These observations suggest that the p.I11T mutation results in constitutive FPR1 desensitization that results in constitutive b-arrestin endocytosis similar to what is observed for a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus 27 The constitutive recruitment of b-arrestin by the p.I11T FPR1 variant may also be linked to the increased granule release observed in subjects with the allele, because we have demonstrated previously that b-arrestin signaling is linked to granule release. 28 However, the observation that an extracellular tail domain mutation leads to agonist-independent receptor activity is unique as most constitutively activating/desensitizing mutations have been localized to intracellular loop and transmembrane spanning domains of GPCRs.
CRP -a clinical biomarker of inflammation -has been suggested to be both a predictor of atherosclerotic vascular events and a target for intervention. 29 So far, only the CRP gene on chromosome 1q21 has been shown to be a determinant of serum CRP in the subpopulations. 30, 31 Our data suggest that common, functional genetic variation in FPR1 is also correlated with increased CRP levels. Considering that a link between CRP and fMLP signaling has been documented, the FPR1 p.I11T variant may function as a contributory factor linked to cardiovascular risk. For example, in rabbit lungs pretreatment of animals with CRP inhibits increased pulmonary permeability that is induced by fMLP. 32 Furthermore, new findings suggest that CRP may initially play a more generalized anti-inflammatory role in the regulation of fMLP. First, CRP inhibits phorbol esterand fMLP-stimulated superoxide production. 33 Second, CRP blocks fMLP-stimulated chemotaxis and fMLP-induced p38 MAK kinase activation required for this response. [34] [35] [36] Finally, in mouse models of systemic lupus erythematosus, injection of CRP delays mortality. 37 The observed increases in CRP levels may represent an adaptive physiological response to ameliorate increased systemic inflammation that may be associated with increased basal granule release observed for subjects with the FPR1 p.I11T genotype. Thus, it would be of future interest to evaluate the association of FPR1 p.I11T genotype with CRP and cardiovascular phenotypes in samples taken from various ethnic groups.
In summary, we have identified a novel FPR1 p.I11T genotype that is associated with increased inflammatory indices in a normotensive subject population. The FPR1 pI11T phenotype appears to involve the agonist-independent recruitment of b-arrestin that is associated with increased basal release of N-acetyl-D-glucosaminidase from primary neutrophils isolated from subjects either heterozygous or homozygous for the p.I11T FPR1 variant. This observation, taken together with the observed increase in CRP levels associated with the FPR1 p.I11T genotype predicts that carriers of the p.I11T allele, particularly homozygotes, may be at increased risk of diseases associated with inflammation. Additional prospective and longitudinal studies in larger human samples will be required to validate this prediction.
Materials and methods

Materials
HEK 293 and RBL-2H3 cells lines were obtained from American Type Culture Collection (Manassas, VA, USA). Fetal bovine serum, gentamicin, minimal essential medium (MEM), RPMI 1640 and Trypsin-ethylene diaminetetra acetic acid (EDTA) was purchased from Invitrogen, San Diego, CA, USA. Eagle's modified essential medium (EMEM) was bought from Biowhittaker (Walkerswille, MD, USA). The agonist fMLP was purchased from Sigma (Misissauga, ON, Canada).
Construction of GFP-tagged FPR1s
All recombinant cDNA procedures were carried out following standard protocols. Both the wild-type and p.I11T FPR1 variant were identified in a Marathon-Ready human fetal brain cDNA library (Clontech) during the cloning of the FPR1. 13 To construct fMLP-pEGFPN1 receptors, FPR1 cDNAs were amplified by nested polymerase chain reaction (PCR) from Marathon-Ready human fetal brain cDNA library (Clontech) according to the manufacturer's protocols. 5 0 and 3 0 primers used in the nested PCR contained BglII and EcoRI restriction site sequences, respectively. The FPR1 PCR product was digested with the appropriate restriction enzymes and the FPR1 cDNA cloned into the corresponding sites of the vector pEGFPN1 (Clontech). The I11T SNP in the FPR1 was identified in four independent clones. FPR1s were also subcloned into hemagglutanin (HA) tagged pcDNA3 (Invitrogen).
Cell culture and transfections HEK 293 cells were grown in MEM supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) and gentamicin (100 mg/ml). The cells were seeded at a density of 2.5 Â 10 6 /100 mm dish (Falcon) and were transiently transfected by a modified calcium phosphate method 38 with the cDNAs described in the figure legends. Following transfection (18 h), the cells were pooled and re-seeded into 35 mm glass-bottomed culture dishes (MatTek, Ashland, MA, USA) for confocal studies. RBL-2H3 cells were grown in EMEM containing 10% FBS and 1:100 dilution of penicillin/ streptomycin (Biowhittaker). Stable transfections were developed as described previously. 13 Briefly, cells were grown to 80% confluence in 100-mm dishes (Falcon) and transfected with 1 mg of FPR1-EGFP using Lipofectamine (Invitrogen). At 72 h days after transfection, cells were harvested, diluted and re-plated in media containing 1 mg/ ml Geneticin (Invitrogen). The media was replaced every 3 days and stable transformants isolated in approximately 3 weeks.
Confocal microscopy
Confocal microscopy was performed on a Zeiss LSM-510 META laser scanning microscope using a Zeiss Â 63 1.3 NA oil immersion lens, using filters with emission wavelengths of 488 and 514 nm. Live cell imaging of HEK 293 expressing GFP-tagged FPR1 was performed using cells plated on 35 mm glass-bottomed culture dishes. The cells were kept warm at 371C on a heated microscope stage as described previously. 13 Constitutive receptor internalization was observed in HEK 293 cells expressing HA-FPR1 and b-arrestin 2-GFP. Anti-HA antibody was conjugated to Alexa Fluor 555 using a Zenon IgG labeling kit (Molecular Probes, Eugene, OR, USA) following the manufacturer's directions. Cell-surface HA-FPR1 were labeled by the addition of Alexa Fluor 555 labeled anti-HA antibody diluted 1:500 in HBSS to the cell cultures, and image collection was started 10 min after the addition of antibody to the medium using the Zeiss LSM physiological software time scan function. The internalization of the receptor and its colocalization with b-arrestin 2-GFP were observed before and after fMLP treatment.
Receptor internalization
The agonist-independent internalization of HA-FPR1 and HA-tagged p.I11T FPR1 was measured by flow cytometry as described previously. 18 Cell surface epitope-tagged receptors were prelabeled with primary anti-mouse HA antibody (1:500) on ice for 45 min. Cells were then warmed to 371C for the times indicated in the figure legends. Cells were then transferred back on ice and labeled with secondary fluorescein isothiocyanate-conjugated anti-mouse IgG antibody (1:500 dilution) for 45 min. Under these conditions, receptors are able to undergo only a single round of internalization. Receptor internalization is defined as the fraction of total cell receptors lost from the cell surface and thus not available for labeling with the secondary antibody.
Isolation of human neutrophils
Freshly drawn peripheral venous blood from healthy blood donors was collected into vacutainer tubes containing EDTA (Becton Dickinson, Mississauga, ON, Canada). Neutrophils were isolated by Ficoll gradient centrifugation, purified by dextran sedimentation and hypotonic lysis of red blood cells as described. 39, 40 Purified PMNs were resuspended in RPMI 1640 supplemented with 10% FBS and kept on ice before stimulation with fMLP. fMLP was used at a final concentration of 100 nM in all experiments described in this paper. Informed consent was obtained for all analyses, with approval from the University of Western Ontario Research Ethics Review Board.
Secretion assay
Isolated neutrophils (10 Â 10 6 ) expressing FPR1 constructs were seeded onto six-well plates 2 h before agonist stimulation in serum-free RPMI 1640 or Dulbecco's modified Eagle's medium. Upon stimulation with fMLP (100 nM) at 371C for 10 min, the samples were processed and the release of N-acetyl-D-glucosaminidase was measured as described previously. 40 Supernatants containing N-acetyl-D-glucosaminidase were incubated with 1 mM p-(nitrophenyl)-N-acetyl-b-D-glucosamide (Sigma-Aldrich, Misissauga, ON, Canada) for 1 h at 371C and the absorbance was measured at 400 nm.
Flow cytometric analysis of fMLP binding fMLP binding experiments were conducted using a fluorescent labeled fMLP (Molecular Probes) and flow cytometry as described previously. 41 HEK 293 cells transiently expressing the FPR1 were incubated for 1 h on ice with fMLPfluorescein at various concentrations ranging from 1 to 100 nM as indicated in the figure. Cells were then washed 3 times with phosphate-buffered saline. Ligand-stained cells were analyzed for mean fluorescence intensity on a FACScan flow cytometer and the mean fluorescence level was plotted against fMLP concentration. A sample using 1000-fold molar excess of unlabeled-fMLP was included to determine the levels of unspecific binding. The nonspecific binding was calculated as 32.873.7% for the wild type and 29.7711.9% for the p.I11T receptor.
Fluorescence recording of [Ca 2 þ ] i . RBL-2H3 cells were grown and stable transfectants were isolated as described previously. 13 Cells transfected with 10 mg of the wild-type or mutant FPR1 alone or with the vector were trypsinized and transferred to 12 mm glass cover slips a day before the experiments and grown in EMEM (Cambrex, MD, USA) supplemented with fetal bovine serum (10%), L-glutamine 2 mm, sodium pyruvate 100 mm, penicillin (100 U/ml) and streptomycin (100 mg/ml). Intracellular calcium measurements were performed as described. 42 On the day of the experiment, cells were loaded with 2 mm fura 2-AM (Molecular Probes) and 16 mm pluronic acid (Molecular Probes) for 1 h at 371C and then washed with Na þ Ringer solution consisting of 130 mm NaCl, 5 mm KCl, 10 mm glucose, 1 mm MgCl 2 , 1 mm CaCl 2 and 20 mm N-2-hydroxyl piperazine-N 0 -2-ehane sulfonic acid, pH 7.4, 280-290 mosM. Coverslips containing fura 2-loaded cells were placed in a chamber (0.75 ml) mounted on a Nikon Diaphot inverted microscope and were continuously superfused with the Ringer solution. Fluorescence was measured at 510 nm at excitation wavelengths of 345 and 380 nm. The fluorescence ratio was then used to calculate [Ca 2 þ ] i as described previously. 19 Fields of approximately 30 cells were randomly chosen for measuring the changes in [Ca 2 þ ] i concentration. Cells were stimulated for 20 s using a glass puffer containing fMLP at various concentrations as described in figure legends. Baseline and peak height were determined from smoothed [Ca 2 þ ] i tracings and these recordings were used to compare individual treatments.
Genetic association analysis. In order to define basic population genetics of this SNP and to determine whether Constitutively activating FPR1 SNP and inflammation SNP genotype was associated with clinical phenotypes, we developed an allele-specific genotyping method based on restriction endonuclease digestion. Briefly, we used primers 5 0 -GAA GGT GAG AAA GCT AGG AGT GGG and 5 0 -AGA TAC AGC AGG TGT CCC TCC TGA to amplify the genomic DNA sequence surround codon 11. The reverse primer contained a single nucleotide mismatch to create a Bsu36I endonuclease recognition site. We then amplified 100 ng genomic DNA using 30 cycles of denaturation at 941C, followed by annealing at 601C and extension at 721C. The 177 bp amplified product was digested with endonuclease Bsu36I. For alleles containing C in codon 11 encoding I11, two fragments with sizes 152 and 25 bp were produced by digestion, whereas alleles containing T in codon 11 encoding T11 produced one 177 bp fragment after digestion. Fragments were clearly resolved in 10% polyacrylamide gels. A sequence-proven standard was run with each batch of genotyped samples. Blinded replication analysis of 10% of samples showed no discrepancies between genotypes.
We first determined allele frequencies in healthy control samples from several human populations, including two Caucasian samples and 40 subjects each of African, East Indian and Chinese descent. These were samples of healthy controls of various ethnic backgrounds who have served as reference populations for studies of allele frequencies. We next determined allele frequencies in 369 healthy subjects of native Canadian descent, who again have served as a reference sample for studies of allele frequencies. All subjects provided informed consent for genotyping studies. Finally, genotyping was performed in all individuals who had cellular degranulation experiments and also in two separate cohorts of normal healthy free-living Caucasian volunteers, with no medical history of autoimmune or inflammatory diseases. Subjects with past medical history of autoimmune, inflammatory or cardiovascular disease were excluded from the analysis, as were subjects with acute infections and subjects taking anti-inflammatory medication. The first sample was comprised of 157 healthy Caucasian subjects (48.1% males) with mean7s.d. age of 45.4715.7 years who were all residents of southwestern Ontario and were volunteer participants in a screening survey for cardiovascular risk. The second sample was ascertained through family medicine and metabolism clinics and was comprised of 410 disease-free Caucasian subjects (59.8% males), residents of southwestern Ontario, with mean7s.d. age of 50.4714.1 years. All study subjects had neither a medical history of nor were they receiving treatment for acute or chronic illness, including diabetes, cardiovascular disease or inflammatory diseases. Study subjects had had determinations of total blood leukocyte and neutrophil cell counts, of serum CRP concentration and of ESR.
Data analysis
Quantitative data from in vitro assays were analyzed using an unpaired two-tailed t-test within GraphPad Prism software, San Diego, CA, USA. Other statistical analyses were performed using SAS version 8.0 (SAS Institute, Cary, NC, USA). Deviation of genotype frequencies from HardyWeinberg expectations was assessed using w 2 analysis. For analysis of quantitative clinical variables, statistical significance of the association of independent variables was assessed using analysis of variance (ANOVA) and type III sums of squares, which is most appropriate for unbalanced cell sizes. The dependent variables in the ANOVA were the blood and serum quantitative traits. Transformation with the natural logarithm resulted in a distribution that was not significantly different from normal distribution. In order to adjust for possible effects of age, sex, current smoking and obesity (body mass index (BMI) expressed as kg/m 2 ), these variables were included as covariates. Specific genetic models were evaluated using ANOVA, namely dominant (genotype C/C ¼ 0 and genotype T/C or T/T ¼ 1), additive (genotype C/C ¼ 0, T/C ¼ 0.5 and T/T ¼ 1) and recessive (genotype C/C or T/T ¼ 0 and genotype T/T ¼ 1). A P-value o0.05 was the nominal threshold for significance in all analyses. Dose-response curves were fit using GraphPad Prizm software. 
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